CN102470133B - 含有喹啉衍生物的药物组合物 - Google Patents
含有喹啉衍生物的药物组合物 Download PDFInfo
- Publication number
- CN102470133B CN102470133B CN2010800305086A CN201080030508A CN102470133B CN 102470133 B CN102470133 B CN 102470133B CN 2010800305086 A CN2010800305086 A CN 2010800305086A CN 201080030508 A CN201080030508 A CN 201080030508A CN 102470133 B CN102470133 B CN 102470133B
- Authority
- CN
- China
- Prior art keywords
- quinoline
- pharmaceutical composition
- methoxyl group
- comparative example
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
Description
实施例1 | 实施例2 | 实施例3 | |
化合物A | 1.25 | 5 | 12.5 |
沉淀碳酸钙 | 33 | 33 | 33 |
D-甘露醇 | 19.75 | 16 | 8.5 |
羟丙基纤维素 | 3 | 3 | 3 |
低取代度羟丙基纤维素 | 25 | 25 | 25 |
结晶纤维素(PH-101) | 10 | 10 | 10 |
结晶纤维素(PH-102) | 5 | 5 | 5 |
滑石 | 3 | 3 | 3 |
总计 | 100 | 100 | 100 |
实施例16 | 实施例17 | |
化合物A | 10 | 10 |
沉淀碳酸钙 | 15 | 0 |
碳酸镁 | 0 | 15 |
羟丙基纤维素 | 2 | 2 |
交联羧甲基纤维素钠 | 10 | 10 |
低取代度羟丙基纤维素 | 20 | 20 |
结晶纤维素(PH-102) | 41 | 41 |
滑石 | 2 | 2 |
总计 | 100 | 100 |
比较例5 | 比较例6 | |
化合物A | 10 | 10 |
甘露醇 | 15 | 0 |
滑石 | 0 | 15 |
羟丙基纤维素 | 2 | 2 |
交联羧甲基纤维素钠 | 10 | 10 |
低取代度羟丙基纤维素 | 20 | 20 |
结晶纤维素(PH-102) | 41 | 41 |
滑石 | 2 | 2 |
总计 | 100 | 100 |
实施例18 | 比较例7 | 比较例8 | |
化合物A | 20 | 20 | 20 |
沉淀碳酸钙 | 10 | 0 | 0 |
氧化钙 | 0 | 10 | 0 |
氢氧化钙 | 0 | 0 | 10 |
低取代度羟丙基纤维素 | 20 | 20 | 20 |
D-甘露醇 | 47 | 47 | 47 |
滑石 | 3 | 3 | 3 |
总计 | 100 | 100 | 100 |
实施例19 | 比较例9 | 比较例10 | |
化合物A | 20 | 20 | 20 |
碳酸镁 | 10 | 0 | 0 |
氧化镁 | 0 | 10 | 0 |
氢氧化镁 | 0 | 0 | 10 |
低取代度羟丙基纤维素 | 20 | 20 | 20 |
D-甘露醇 | 47 | 47 | 47 |
滑石 | 3 | 3 | 3 |
总计 | 100 | 100 | 100 |
Claims (5)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-190145 | 2009-08-19 | ||
JP2009190145 | 2009-08-19 | ||
PCT/JP2010/063804 WO2011021597A1 (ja) | 2009-08-19 | 2010-08-16 | キノリン誘導体含有医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102470133A CN102470133A (zh) | 2012-05-23 |
CN102470133B true CN102470133B (zh) | 2013-08-28 |
Family
ID=43607048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800305086A Ceased CN102470133B (zh) | 2009-08-19 | 2010-08-16 | 含有喹啉衍生物的药物组合物 |
Country Status (32)
Country | Link |
---|---|
US (3) | US20120077842A1 (zh) |
EP (1) | EP2468281B1 (zh) |
JP (1) | JP5048871B2 (zh) |
KR (1) | KR101496395B1 (zh) |
CN (1) | CN102470133B (zh) |
AU (1) | AU2010285740C1 (zh) |
BR (1) | BR112012003592B8 (zh) |
CA (1) | CA2771403C (zh) |
CL (1) | CL2012000412A1 (zh) |
CO (1) | CO6440512A2 (zh) |
CY (1) | CY1117481T1 (zh) |
DK (1) | DK2468281T3 (zh) |
ES (1) | ES2564797T3 (zh) |
HK (2) | HK1167607A1 (zh) |
HR (1) | HRP20160283T1 (zh) |
HU (1) | HUE026957T2 (zh) |
IL (1) | IL217197A (zh) |
MA (1) | MA33581B1 (zh) |
ME (1) | ME02359B (zh) |
MX (2) | MX2012002011A (zh) |
MY (1) | MY162940A (zh) |
NZ (1) | NZ598291A (zh) |
PE (1) | PE20121030A1 (zh) |
PL (1) | PL2468281T3 (zh) |
RS (1) | RS54686B1 (zh) |
RU (1) | RU2548673C3 (zh) |
SG (1) | SG178009A1 (zh) |
SI (1) | SI2468281T1 (zh) |
SM (1) | SMT201600077B (zh) |
UA (1) | UA105671C2 (zh) |
WO (1) | WO2011021597A1 (zh) |
ZA (1) | ZA201108697B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
CN106139156B (zh) * | 2014-11-14 | 2019-01-29 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
SG11201706630UA (en) * | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
CN106075456A (zh) * | 2015-04-27 | 2016-11-09 | 南京圣和药业股份有限公司 | 一种含乐伐替尼的药物组合物及其应用 |
MX2017014799A (es) * | 2015-05-21 | 2023-02-23 | Crystal Pharmatech Co Ltd | Forma cristalina novedosa de mesilato de lenvatinib y procedimiento de preparacion de la misma. |
MX2017015896A (es) | 2015-06-16 | 2018-08-09 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
CN106999483B (zh) * | 2015-08-17 | 2019-05-03 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物 |
RU2606592C1 (ru) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты) |
CZ2016240A3 (cs) | 2016-04-27 | 2017-11-08 | Zentiva, K.S. | Soli lenvatinibu |
EP3384901A1 (en) * | 2017-04-04 | 2018-10-10 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib mesylate |
US10583133B2 (en) | 2018-03-12 | 2020-03-10 | Shilpa Medicare Limited | Pharmaceutical compositions of lenvatinib |
CN110404079B (zh) * | 2018-04-27 | 2023-01-24 | 北京睿创康泰医药研究院有限公司 | 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物 |
CA3113549A1 (en) | 2018-10-04 | 2020-04-09 | Synthon B.V. | Crystalline forms and processes of lenvatinib besylate |
ES2922903T3 (es) | 2018-10-04 | 2022-09-21 | Synthon Bv | Composición farmacéutica que comprende sales de lenvatinib |
CN113087666B (zh) * | 2020-01-09 | 2021-12-14 | 南京正大天晴制药有限公司 | 无定形喹啉甲酰胺衍生物的制备方法 |
WO2021185006A1 (zh) * | 2020-03-18 | 2021-09-23 | 上海博志研新药物技术有限公司 | 一种仑伐替尼药物组合物、其制备方法及应用 |
EP4147689A1 (en) | 2021-09-13 | 2023-03-15 | Lotus Pharmaceutical Co., Ltd. | Lenvatinib formulation |
CN114306271B (zh) * | 2021-11-24 | 2023-04-07 | 石药集团中奇制药技术(石家庄)有限公司 | 一种仑伐替尼组合物 |
CN115671074A (zh) * | 2022-11-15 | 2023-02-03 | 郑州德迈药业有限公司 | 一种甲磺酸仑伐替尼制剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478078A (zh) * | 2000-10-20 | 2004-02-25 | ������������ʽ���� | 含氮芳环衍生物 |
WO2004080462A1 (ja) * | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kitキナーゼ阻害剤 |
CN1890220A (zh) * | 2003-12-25 | 2007-01-03 | 卫材株式会社 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法 |
CN101001629A (zh) * | 2004-09-17 | 2007-07-18 | 卫材R&D管理有限公司 | 药物组合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1458148A (en) * | 1974-04-19 | 1976-12-08 | Wyeth John & Brother Ltd | Carbocyclic-fused ring quinoline derivatives |
US5009894A (en) * | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
EP2596792A1 (en) * | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
JP2006511486A (ja) * | 2002-10-21 | 2006-04-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Crth2拮抗剤としてのテトラヒドロキノリン誘導体 |
JP4733700B2 (ja) * | 2005-06-23 | 2011-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩のアモルファスおよびその製造方法 |
US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
JP2011516412A (ja) * | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス,エルエルシー | 癌および粘膜炎の治療のための組成物および方法 |
-
2010
- 2010-08-16 MY MYPI2011700172A patent/MY162940A/en unknown
- 2010-08-16 SI SI201031141A patent/SI2468281T1/sl unknown
- 2010-08-16 PL PL10809938T patent/PL2468281T3/pl unknown
- 2010-08-16 JP JP2011527665A patent/JP5048871B2/ja active Active
- 2010-08-16 CN CN2010800305086A patent/CN102470133B/zh not_active Ceased
- 2010-08-16 SG SG2011086022A patent/SG178009A1/en unknown
- 2010-08-16 MX MX2012002011A patent/MX2012002011A/es unknown
- 2010-08-16 NZ NZ598291A patent/NZ598291A/xx unknown
- 2010-08-16 ME MEP-2016-45A patent/ME02359B/me unknown
- 2010-08-16 CA CA2771403A patent/CA2771403C/en active Active
- 2010-08-16 ES ES10809938.3T patent/ES2564797T3/es active Active
- 2010-08-16 AU AU2010285740A patent/AU2010285740C1/en active Active
- 2010-08-16 BR BR112012003592A patent/BR112012003592B8/pt active IP Right Grant
- 2010-08-16 HU HUE10809938A patent/HUE026957T2/en unknown
- 2010-08-16 MX MX2014010594A patent/MX344927B/es unknown
- 2010-08-16 RU RU2012103471A patent/RU2548673C3/ru active Protection Beyond IP Right Term
- 2010-08-16 EP EP10809938.3A patent/EP2468281B1/en active Active
- 2010-08-16 DK DK10809938.3T patent/DK2468281T3/en active
- 2010-08-16 KR KR1020127003846A patent/KR101496395B1/ko active Protection Beyond IP Right Term
- 2010-08-16 WO PCT/JP2010/063804 patent/WO2011021597A1/ja active Application Filing
- 2010-08-16 PE PE2011002081A patent/PE20121030A1/es active IP Right Grant
- 2010-08-16 UA UAA201203132A patent/UA105671C2/uk unknown
- 2010-08-16 RS RS20160176A patent/RS54686B1/en unknown
- 2010-08-16 US US13/322,961 patent/US20120077842A1/en not_active Abandoned
-
2011
- 2011-11-25 ZA ZA2011/08697A patent/ZA201108697B/en unknown
- 2011-12-25 IL IL217197A patent/IL217197A/en active IP Right Grant
-
2012
- 2012-02-09 CO CO12022608A patent/CO6440512A2/es not_active Application Discontinuation
- 2012-02-16 CL CL2012000412A patent/CL2012000412A1/es unknown
- 2012-03-12 MA MA34683A patent/MA33581B1/fr unknown
- 2012-08-27 HK HK12108351.2A patent/HK1167607A1/xx not_active IP Right Cessation
- 2012-10-17 HK HK12110288.6A patent/HK1169599A1/zh unknown
-
2013
- 2013-06-21 US US13/923,858 patent/US20130296365A1/en not_active Abandoned
-
2016
- 2016-03-17 SM SM201600077T patent/SMT201600077B/xx unknown
- 2016-03-18 HR HRP20160283TT patent/HRP20160283T1/hr unknown
- 2016-04-05 CY CY20161100273T patent/CY1117481T1/el unknown
-
2021
- 2021-04-12 US US17/228,025 patent/US20210228722A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478078A (zh) * | 2000-10-20 | 2004-02-25 | ������������ʽ���� | 含氮芳环衍生物 |
WO2004080462A1 (ja) * | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kitキナーゼ阻害剤 |
CN1890220A (zh) * | 2003-12-25 | 2007-01-03 | 卫材株式会社 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法 |
CN101001629A (zh) * | 2004-09-17 | 2007-07-18 | 卫材R&D管理有限公司 | 药物组合物 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US9504746B2 (en) | 2004-09-17 | 2016-11-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102470133B (zh) | 含有喹啉衍生物的药物组合物 | |
CN100562317C (zh) | 含大量酸不稳定药物的颗粒 | |
CN101141961B (zh) | 索非那新或其盐的稳定的颗粒状药物组合物 | |
CA2552463C (en) | New compositions containing quinoline compounds | |
CN104105490A (zh) | 口服用医药组合物 | |
CN110693839B (zh) | 一种甲磺酸仑伐替尼固体分散体及其制备方法和用途 | |
CN110404079B (zh) | 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物 | |
CN102058878B (zh) | 一种胃内生成大蒜辣素的前体微丸片及其制备方法 | |
CN104721828A (zh) | 一种改善晶体药物稳定性的药物组合物及其制备方法 | |
JP4292588B2 (ja) | ピリダジノン化合物類の経口製剤 | |
JP4774739B2 (ja) | 漢方エキス含有錠剤組成物およびその製造方法 | |
CN106075456A (zh) | 一种含乐伐替尼的药物组合物及其应用 | |
JP2020518611A (ja) | 水溶解度及びバイオアベイラビリティが改善された組成物 | |
CA3108993C (en) | Pharmaceutical composition for oral administration | |
TWI501950B (zh) | 含喹啉衍生物的藥學組成物 | |
CN114948954B (zh) | 一种含甲磺酸仑伐替尼组合物及其制备方法、用途 | |
CN102670533A (zh) | 稳定的阿立哌唑口腔崩解片及其制备方法 | |
JP2010260851A (ja) | ジベンゾ[b,e]オキセピン誘導体を含有する固形製剤 | |
KR100464210B1 (ko) | 세푸록심 악세틸 함유 약제학적 조성물 및 그의 제조방법 | |
CN101491524A (zh) | 具有改善西替利嗪制剂稳定性的药物组合物 | |
CN100333717C (zh) | 替加色罗马来酸盐口服固体制剂 | |
CN113491695A (zh) | 一种仑伐替尼药物组合物、其制备方法及应用 | |
KR20010004162A (ko) | 미립자화된 이트라코나졸 함유 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1167607 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1167607 Country of ref document: HK |
|
IW01 | Full invalidation of patent right | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20210525 Decision number of declaring invalidation: 49805 Granted publication date: 20130828 |